FDA expands Mounjaro use to reduce heart risk in high‑risk diabetics
TL;DR Summary
The FDA broadened Mounjaro’s use to lower major cardiovascular events in high‑risk adults with type 2 diabetes, with Lilly citing an additional 8% reduction versus Trulicity; the same drug is sold as Zepbound for weight loss, and Lilly is pursuing newer hormone‑targeting therapies.
- FDA approves new use of popular diabetes drug Action News 5
- Eli Lilly's diabetes drug Mounjaro gets approval for a new use USA Today
- FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes Eli Lilly and Company
- Mounjaro scores FDA approval to reduce CV risk; Teva to buy an approved drug Endpoints News
- Mounjaro Is Now Approved to Lower the Risk of Heart Events Time Magazine
Reading Insights
Total Reads
1
Unique Readers
3
Time Saved
0 min
vs 1 min read
Condensed
57%
99 → 43 words
Want the full story? Read the original article
Read on Action News 5